| Year |
Citation |
Score |
| 2018 |
Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, et al. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Scientific Reports. 8: 6574. PMID 29700408 DOI: 10.1038/S41598-018-23733-4 |
0.534 |
|
| 2018 |
Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, ... Horne HN, et al. FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29650751 DOI: 10.1158/1078-0432.Ccr-18-0042 |
0.343 |
|
| 2018 |
Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: the Susan G. Komen Tissue Bank. International Journal of Cancer. PMID 29473153 DOI: 10.1002/Ijc.31333 |
0.304 |
|
| 2017 |
Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, et al. FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28751443 DOI: 10.1158/1078-0432.CCR-17-1337 |
0.364 |
|
| 2016 |
Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, et al. Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. Plos One. 11: e0160316. PMID 27556229 DOI: 10.1371/Journal.Pone.0160316 |
0.477 |
|
| 2016 |
Oh H, Khodr ZG, Sherman ME, Palakal M, Pfeiffer RM, Linville L, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Falk RT, Horne HN, Papathomas D, Patel DA, Xiang J, et al. Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy. Hormones & Cancer. PMID 27138982 DOI: 10.1007/S12672-016-0265-2 |
0.334 |
|
| 2016 |
Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, Pollak M, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, et al. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research : Bcr. 18: 24. PMID 26893016 DOI: 10.1186/S13058-016-0678-4 |
0.378 |
|
| 2016 |
Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SH, Schmidt M, Benitez J, Milne R, Brenner H, Nevanlinna H, Mannermaa A, Chenevix-Trench G, Couch F, Devilee P, Eccles D, et al. Abstract 3451: Breast cancer risk factor associations by loss of E-cadherin tumor tissue expression: A pooled analysis of 5,896 cases in 12 studies from the Breast Cancer Association Consortium (BCAC) Cancer Research. 76: 3451-3451. DOI: 10.1158/1538-7445.Am2016-3451 |
0.598 |
|
| 2015 |
Gierach GL, Patel DA, Pfeiffer RM, Figueroa JD, Linville LM, Papathomas D, Johnson JM, Chicoine RE, Herschorn S, Shepherd J, Wang J, Malkov S, Vacek PM, Weaver DL, Fan B, ... ... Horne HN, et al. Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities. Cancer Prevention Research (Philadelphia, Pa.). PMID 26645278 DOI: 10.1158/1940-6207.Capr-15-0282 |
0.457 |
|
| 2015 |
Figueroa JD, Yang H, Garcia-Closas M, Davis S, Meltzer P, Lissowska J, Horne HN, Sherman ME, Lee M. Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. Breast Cancer Research and Treatment. 150: 457-66. PMID 25773928 DOI: 10.1007/S10549-015-3314-6 |
0.564 |
|
| 2015 |
Horne HN, Beena Devi CR, Sung H, Tang TS, Rosenberg PS, Hewitt SM, Sherman ME, Anderson WF, Yang XR. Greater absolute risk for all subtypes of breast cancer in the US than Malaysia. Breast Cancer Research and Treatment. 149: 285-91. PMID 25537643 DOI: 10.1007/S10549-014-3243-9 |
0.492 |
|
| 2014 |
Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J, Brinton LA, Prokunina-Olsson L, Dawson SJ, Caldas C, Easton DF, Chanock SJ, et al. Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Research and Treatment. 143: 181-7. PMID 24292867 DOI: 10.1007/s10549-013-2771-z |
0.514 |
|
| 2013 |
Chawla N, Kepka DL, Heckman-Stoddard BM, Horne HN, Felix AS, Luhn P, Pelser C, Barkley J, Faupel-Badger JM. Health disparities around the world: perspectives from the 2012 Principles and Practice of Cancer Prevention and Control course at the National Cancer Institute. Journal of Oncology Practice / American Society of Clinical Oncology. 9: e284-9. PMID 24084887 DOI: 10.1200/Jop.2013.001129 |
0.388 |
|
| 2012 |
Horne HN, Sherman ME, Yang XR, Garcia-Closas M, Lissowska J, Brinton LA, Chanock SJ, Figueroa JD. Abstract LB-336: Association of variant rs2046210 at 6q25.1 (ESR1) with breast cancer risk suggests heterogeneity by E-cadherin tumor tissue expression Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-336 |
0.514 |
|
| 2012 |
Horne H, Sherman M, Garcia-Closas M, Pharoah P, Blows F, Yang X, Lissowska J, Brinton L, Chanock S, Figueroa J. Abstract P3-08-02: Common variants at 10p14 and 1p11.2 display heterogeneity in breast cancer associations by E-cadherin tumor tissue expression in two independent datasets Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-08-02 |
0.469 |
|
| 2009 |
Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2448-55. PMID 19318476 DOI: 10.1158/1078-0432.Ccr-08-2430 |
0.433 |
|
| 2009 |
Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Molecular Cancer Research : McR. 7: 199-209. PMID 19208741 DOI: 10.1158/1541-7786.Mcr-08-0314 |
0.472 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2015 |
Yu K, Zhang H, Wheeler W, Horne HN, Chen J, Figueroa JD. A robust association test for detecting genetic variants with heterogeneous effects. Biostatistics (Oxford, England). 16: 5-16. PMID 25057183 DOI: 10.1093/Biostatistics/Kxu036 |
0.231 |
|
| 2015 |
Horne HN, Phelan-Emrick DF, Pollack CE, Markakis D, Wenzel J, Ahmed S, Garza MA, Shapiro GR, Bone LR, Johnson LB, Ford JG. Effect of patient navigation on colorectal cancer screening in a community-based randomized controlled trial of urban African American adults. Cancer Causes & Control : Ccc. 26: 239-46. PMID 25516073 DOI: 10.1007/S10552-014-0505-0 |
0.198 |
|
| 2004 |
Brylawski BP, Cohen SM, Horne H, Irani N, Cordeiro-Stone M, Kaufman DG. Transitions in replication timing in a 340 kb region of human chromosomal R-Band 1p36.1. Journal of Cellular Biochemistry. 92: 755-69. PMID 15211573 DOI: 10.1002/Jcb.20101 |
0.096 |
|
| 2019 |
Horne HN, Roscoe D, Litwack ED, Pathak A, Pandey JP, Gallagher PS, Koontz LM, Schuck RN, Lee EY, Hu YF, Beaver JA, Blumenthal GM, Philip R. Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop Proceedings. Jco Precision Oncology. 3. PMID 32914013 DOI: 10.1200/PO.18.00314 |
0.034 |
|
| Hide low-probability matches. |